5-(4-methoxybenzoyl)-N-(p-tolyl)hydrazine-1-carboxamide | 445008-27-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4-methoxybenzoyl)-N-(p-tolyl)hydrazine-1-carboxamide
• 英文别名: 2-(4-methoxybenzoyl)-N-(4-methylphenyl)hydrazinecarboxamide；1-[(4-methoxybenzoyl)amino]-3-(4-methylphenyl)urea
• CAS: 445008-27-5
• 化学式: C₁₆H₁₇N₃O₃
• 分子量: 299.329
• InChiKey: CNRWOGBSVPOFIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.47
• 重原子数：
  22.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.46
• 氢给体数：
  3.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  5-(4-methoxybenzoyl)-N-(p-tolyl)hydrazine-1-carboxamide 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 24.0h， 生成 N-(4-chlorophenyl)-3-(4-methoxyphenyl)-5-oxo-4-(p-tolyl)-4,5-dihydro-1H-1,2,4-triazole-1-carboxamide
  参考文献：
  名称：

  Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists

  摘要：

  Cannabinoids are potentially useful for the treatment of several diseases. In the present work, we report the syntheses and biological evaluations of 1,2,4-triazolone derivatives designed using a combined approach of scaffold hopping and pharmacophore-oriented method. These compounds exhibited interesting antagonistic activity to the cannabinoid CBI receptor. The preliminary structure activity relationships were further discussed. In addition, docking simulations were performed on the good bioactive compound 5c and the low potent compound 5d, respectively, on the basis of homology models of the CBI and CB2 receptors, which were constructed based on human beta 2-adrenoreceptor and optimized in a membrane environment by MD simulations. Calculation of the binding modes gave us insights into the structural requirements for improving the cannabinoid receptor bioactivity and selectivity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.12.018
• 作为产物：
  描述：

  4-甲氧基苯甲酸甲酯 在 hydrazine hydrate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 29.0h， 生成 5-(4-methoxybenzoyl)-N-(p-tolyl)hydrazine-1-carboxamide
  参考文献：
  名称：

  Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists

  摘要：

  Cannabinoids are potentially useful for the treatment of several diseases. In the present work, we report the syntheses and biological evaluations of 1,2,4-triazolone derivatives designed using a combined approach of scaffold hopping and pharmacophore-oriented method. These compounds exhibited interesting antagonistic activity to the cannabinoid CBI receptor. The preliminary structure activity relationships were further discussed. In addition, docking simulations were performed on the good bioactive compound 5c and the low potent compound 5d, respectively, on the basis of homology models of the CBI and CB2 receptors, which were constructed based on human beta 2-adrenoreceptor and optimized in a membrane environment by MD simulations. Calculation of the binding modes gave us insights into the structural requirements for improving the cannabinoid receptor bioactivity and selectivity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.12.018

文献信息

• T3P as an efficient cyclodehydration reagent for the one-pot synthesis of 2-amino-1,3,4-oxadiazoles
  作者：ANDIVELU ILANGOVAN、SHANMUGASUNDAR SARAVANAKUMAR、SIDDAPPA UMESH

  DOI：10.1007/s12039-015-0834-x

  日期：2015.5

  and environmentally friendly one-pot method for the synthesis of 2-amino-1,3,4-oxadiazoles from acylhydrazides and isocyanates has been achieved with propane phosponic anhydride (T3P) acting as cyclodehydrating reagent. A one-pot synthesis of 2-amino-1,3,4-oxadiazoles from acylhydrazides and isocyanates via cyclodehydration of the acyl semicarbazides, formed in situ, by T3P has been developed.

  用丙烷膦酸酐（T3P）作为环脱水剂，已经实现了从酰基肼和异氰酸酯合成2-氨基-1,3,4-恶二唑的可扩展，环保的一锅法。 已经开发了通过酰肼和异氰酸酯通过T3P原位形成的酰基氨基脲的环化脱水一锅合成2-氨基-1,3,4-恶二唑的方法。
• SMALL MOLECULE INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170298056A1

  公开（公告）日：2017-10-19

  Described herein are small-molecule compounds that specifically inhibit a wide range of HIV-1 isolates without interfering with CD4 or CCR5 binding. Methods of using die compounds for treating or preventing HIV infection are also described.